Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2018’, provides an overview of the Thrombotic Thrombocytopenic Purpura pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura

- The report reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Thrombotic Thrombocytopenic Purpura therapeutics and enlists all their major and minor projects

- The report assesses Thrombotic Thrombocytopenic Purpura therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Thrombotic Thrombocytopenic Purpura

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Kaketsuken

Lee's Pharmaceutical Holdings Ltd

Sanofi

Shire Plc

Kaketsuken

Lee's Pharmaceutical Holdings Ltd

Sanofi

Shire Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Overview

Thrombotic Thrombocytopenic Purpura ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Overview

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Companies Involved in Therapeutics Development

Kaketsuken

Lee's Pharmaceutical Holdings Ltd

Sanofi

Shire Plc

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Drug Profiles

caplacizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate ADAMTS13 for Thrombotic Thrombocytopenic Purpura - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHP-655 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZK-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Product Development Milestones

Featured News & Press Releases

Sep 21, 2018: A Trojan Horse delivery of possible treatment for a rare, potentially deadly, blood-clotting disorder

Sep 03, 2018: Sanofi’s Cablivi receives EC approval to treat rare blood disorder

Jun 29, 2018: Sanofi: CHMP recommends approval of Cablivi (caplacizumab)

Dec 21, 2017: Ablynx Announces Positive Data From Its Japanese Ethno-Bridging Study Of Caplacizumab

Dec 12, 2017: Ablynx Reports Additional Clinically Important Benefits of Caplacizumab From its Phase III Hercules Study in Acquired TTP

Dec 07, 2017: Ablynx Will Host a Webcast to Discuss Additional Data From its Phase III Hercules Study of Caplacizumab in Acquired TTP Following Ash Late-Breaking Data Presentation

Nov 21, 2017: Results From the Phase III Hercules Study of Caplacizumab for the Treatment of Acquired TTP Selected For Presentation In The Late-Breaking Abstracts Session at The 2017 Ash Annual Meeting

Oct 16, 2017: Ablynx Establishes Subsidiary in the USA and Appoints a General Manager

Oct 02, 2017: Ablynx Announces Positive Top line Results From The Phase III Hercules Study Of Caplacizumab For The Treatment Of Acquired TTP

Sep 14, 2017: Engineered Therapy for Blood Clotting Disorder Shows Early Promise

Jul 26, 2017: Ablynx Receives Fast Track Designation From The FDA For Caplacizumab For The Treatment Of Acquired TTP

Jun 26, 2017: Ablynx Initiates a Single And Multiple Dose Phase I Study of Caplacizumab in Healthy Japanese Subjects

May 02, 2017: Ablynx Completes Patient Recruitment in its Phase III Hercules Study of Caplacizumab for the Treatment of aTTP

Mar 22, 2017: Shire receives FDA Fast Track designation for recombinant ADAMTS13 (SHP655) for treatment of hereditary thrombotic thrombocytopenic purpura

Feb 06, 2017: Ablynx Submits a Marketing Authorization Application to the European Medicines Agency for Caplacizumab, Its Anti-vWF Nanobody, for the Treatment of aTTP

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Tables

Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Kaketsuken, H2 2018

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Sanofi, H2 2018

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Shire Plc, H2 2018

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects, H2 2018

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Figures

Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports